Back to results
US 5,430,162 AGranted
7-(substituted)-8-(substituted)-9-substituted amino)-6-demethyl-6-deoxytetracyclines
AssigneeAmerican Cyanamid Company
InventorsPhaik-Eng Sum, Ving J. Lee, Joseph J. Hlavka, Raymond T. Testa
Life of this patent
Estimating the term…
Abstract
The invention provides compounds of formula ##STR1## wherein X, R and R.sup.1 are defined in the specification. These compounds are useful as antibiotic agents.
Claims4
A compound of the formula:
- ##STR225## wherein:
- X is selected from halogen or trifluoromethylsulfonyloxy;
- the halogen is selected from bromine, chlorine, or fluorine;
- R and R.sup.1 are the same or different and are selected from halogen selected from chlorine, bromine, fluorine or iodine;
- or --NR.sup.2 R.sup.3 ;
- R.sup.2 is selected from hydrogen, methyl, or ethyl and R.sup.3 is selected from hydrogen, methyl, ethyl, R.sup.4 (CH.sub.2).sub.n CO-- or R.sup.4' (CH.sub.2).sub.n SO.sub.2 --, n is 0-4, with the proviso that when R or R.sup.1 .dbd.NR.sup.2 R.sup.3 and R.sup.2 .dbd.methyl or ethyl, R.sup.3 .dbd.methyl or ethyl;
- and when R or R.sup.1 .dbd.NR.sup.2 R.sup.3 and R.sup.2 .dbd.hydrogen, R.sup.3 is selected from hydrogen, R.sup.4 (CH.sub.2).sub.n CO-- or R.sup.4' (CH.sub.2).sub.n SO.sub.2 --;
- and when R.sup.3 .dbd.R.sup.4 (CH.sub.2).sub.n CO-- and n=0,
- R.sub.4 is selected from hydrogen;
- (C.sub.1 -C.sub.2) alkyl group selected from methyl or ethyl;
- a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, or S heteroatom optionally having a benzo or pyrido ring fused thereto selected from ##STR226## or a five membered aromatic ring with two N, O or S heteroatoms optionally having a benzo or pyrido ring fused thereto selected from ##STR227## wherein Z and Z.sup.1 .dbd.N, O, or S;
- (C.sub.1 -C.sub.4)alkoxy group;
- C.sub.6 -aryloxy group selected from phenoxy or substituted phenoxy with substitution selected from halo, (C.sub.1 -C.sub.4)alkyl, (C.sub.7 -C.sub.10)aralkyloxy .alpha.-aminomethoxycarbonyl, or halomethoxycarbonyl;
- and when R.sup.3 .dbd.R.sup.4 (CH.sub.2).sub.n CO-- and n=1-4,
- R.sup.4 is selected from hydrogen;
- (C.sub.1 -C.sub.2)alkyl group selected from methyl or ethyl;
- (C.sub.6 -C.sub.10)aryl group selected from phenyl, .alpha.-naphthyl or .beta.-naphthyl;
- and when R.sup.3 .dbd.R.sup.4 (CH.sub.2).sub.n SO.sub.2 -- and n=0, R.sup.4' is selected from (C.sub.1 -C.sub.2)alkyl group selected from methyl or ethyl;
- (C.sub.6 -C.sub.10)aryl group selected from phenyl, .alpha.-naphthyl or .beta.-naphthyl;
- R.sup.5 is selected from hydrogen;
- straight or branched (C.sub.1 -C.sub.3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl;
- R.sup.6 is selected from hydrogen;
- straight or branched (C.sub.1 -C.sub.3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl;
- with the proviso that R.sup.5 and R.sup.6 cannot both be hydrogen;
- or R.sup.5 and R.sup.6 taken together are --(CH.sub.2).sub.2 W(CH.sub.2).sub.2 --, wherein W is selected from (CH.sub.2).sub.m where m=0-1, --NH,--N(C.sub.1 -C.sub.3)alkyl straight or branched, --N(C.sub.1 -C.sub.4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl (L or D)prolinate, morpholine, pyrrolidine or piperidine;
- and the pharmacologically acceptable organic and inorganic salts or metal complexes.
23 more elements
Dependencies are inferred from the claim text.